This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Raclopride
Accession Number
DB12518
Type
Small Molecule
Groups
Investigational
Description

Raclopride has been used in trials studying Parkinson Disease.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
430K3SOZ7G
CAS number
84225-95-6
Weight
Average: 347.24
Monoisotopic: 346.0850979
Chemical Formula
C15H20Cl2N2O3
InChI Key
WAOQONBSWFLFPE-VIFPVBQESA-N
InChI
InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
IUPAC Name
3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-hydroxy-6-methoxybenzene-1-carboximidic acid
SMILES
[H][C@@]1(CN=C(O)C2=C(O)C(Cl)=CC(Cl)=C2OC)CCCN1CC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UD(2) dopamine receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineRaclopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Raclopride is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineRaclopride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Raclopride.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Raclopride.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Raclopride is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Raclopride.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Raclopride.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Raclopride.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Raclopride.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
3033769
PubChem Substance
347828748
ChemSpider
2298373
BindingDB
50005118
ChEBI
92070
ChEMBL
CHEMBL8809
Wikipedia
Raclopride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableCompletedNot AvailableHealthy Volunteers / Parkinson's Disease (PD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.133 mg/mLALOGPS
logP3.38ALOGPS
logP1.82ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)5.31ChemAxon
pKa (Strongest Basic)9.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area65.29 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity88.59 m3·mol-1ChemAxon
Polarizability35.16 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0119000000-60d7b9266bbc9f46e57c

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Methoxyphenols / 3-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Dichlorobenzenes / Anisoles / Methoxybenzenes / O-chlorophenols / P-chlorophenols / Phenoxy compounds
show 12 more
Substituents
Salicylamide / Methoxyphenol / 3-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / Phenol ether / 4-chlorophenol / 2-chlorophenol / Phenoxy compound / 1,3-dichlorobenzene
show 34 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M: Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology. 2004 Jun;29(6):1190-202. [PubMed:15010698]

Drug created on October 20, 2016 16:41 / Updated on November 02, 2018 07:26